CN102353793A - 白血病细胞内融合蛋白的二元流式液相阵列检测方法 - Google Patents
白血病细胞内融合蛋白的二元流式液相阵列检测方法 Download PDFInfo
- Publication number
- CN102353793A CN102353793A CN2011101899853A CN201110189985A CN102353793A CN 102353793 A CN102353793 A CN 102353793A CN 2011101899853 A CN2011101899853 A CN 2011101899853A CN 201110189985 A CN201110189985 A CN 201110189985A CN 102353793 A CN102353793 A CN 102353793A
- Authority
- CN
- China
- Prior art keywords
- microballoon
- leukaemia
- endonexin
- fluorescence intensity
- hole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000032839 leukemia Diseases 0.000 title claims abstract description 88
- 239000007791 liquid phase Substances 0.000 title claims abstract description 59
- 238000001514 detection method Methods 0.000 title claims abstract description 38
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 20
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 20
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims abstract description 45
- 239000012103 Alexa Fluor 488 Substances 0.000 claims abstract description 35
- 238000000684 flow cytometry Methods 0.000 claims abstract description 6
- 239000012530 fluid Substances 0.000 claims description 46
- 230000004927 fusion Effects 0.000 claims description 46
- 238000002156 mixing Methods 0.000 claims description 38
- 238000013016 damping Methods 0.000 claims description 36
- 238000005406 washing Methods 0.000 claims description 30
- 239000004005 microsphere Substances 0.000 claims description 28
- 238000002360 preparation method Methods 0.000 claims description 26
- 239000000284 extract Substances 0.000 claims description 19
- 101001095089 Homo sapiens PML-RARA-regulated adapter molecule 1 Proteins 0.000 claims description 17
- 102100037019 PML-RARA-regulated adapter molecule 1 Human genes 0.000 claims description 17
- 239000007850 fluorescent dye Substances 0.000 claims description 17
- 239000004793 Polystyrene Substances 0.000 claims description 15
- 229920002223 polystyrene Polymers 0.000 claims description 15
- 238000005576 amination reaction Methods 0.000 claims description 12
- 238000010586 diagram Methods 0.000 claims description 12
- 238000003828 vacuum filtration Methods 0.000 claims description 12
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 claims description 11
- 239000006228 supernatant Substances 0.000 claims description 10
- RPENMORRBUTCPR-UHFFFAOYSA-M sodium;1-hydroxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].ON1C(=O)CC(S([O-])(=O)=O)C1=O RPENMORRBUTCPR-UHFFFAOYSA-M 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 6
- 125000003277 amino group Chemical group 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 238000000751 protein extraction Methods 0.000 claims description 4
- 238000003491 array Methods 0.000 claims description 2
- 238000003306 harvesting Methods 0.000 claims description 2
- MGSKVZWGBWPBTF-UHFFFAOYSA-N aebsf Chemical compound NCCC1=CC=C(S(F)(=O)=O)C=C1 MGSKVZWGBWPBTF-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 18
- 238000003745 diagnosis Methods 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 3
- 238000011160 research Methods 0.000 abstract description 3
- 230000000719 anti-leukaemic effect Effects 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 230000007170 pathology Effects 0.000 abstract description 2
- 230000008030 elimination Effects 0.000 abstract 1
- 238000003379 elimination reaction Methods 0.000 abstract 1
- 238000011534 incubation Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 58
- 239000002953 phosphate buffered saline Substances 0.000 description 21
- 239000000243 solution Substances 0.000 description 14
- 239000007788 liquid Substances 0.000 description 10
- 239000012981 Hank's balanced salt solution Substances 0.000 description 8
- 210000005087 mononuclear cell Anatomy 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- WRDABNWSWOHGMS-UHFFFAOYSA-N AEBSF hydrochloride Chemical compound Cl.NCCC1=CC=C(S(F)(=O)=O)C=C1 WRDABNWSWOHGMS-UHFFFAOYSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000001215 fluorescent labelling Methods 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 210000000349 chromosome Anatomy 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 210000004940 nucleus Anatomy 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000006116 polymerization reaction Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 3
- 239000002853 nucleic acid probe Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000005945 translocation Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 2
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 2
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 2
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 2
- 102000011931 Nucleoproteins Human genes 0.000 description 2
- 108010061100 Nucleoproteins Proteins 0.000 description 2
- 108010004729 Phycoerythrin Proteins 0.000 description 2
- 238000001190 Q-PCR Methods 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 238000010205 computational analysis Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000011325 microbead Substances 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- WKVZMKDXJFCMMD-UVWUDEKDSA-L (5ar,8ar,9r)-5-[[(2r,4ar,6r,7r,8r,8as)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one;azanide;n,3-bis(2-chloroethyl)-2-ox Chemical compound [NH2-].[NH2-].Cl[Pt+2]Cl.ClCCNP1(=O)OCCCN1CCCl.COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3C(O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 WKVZMKDXJFCMMD-UVWUDEKDSA-L 0.000 description 1
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- CWHJIJJSDGEHNS-MYLFLSLOSA-N Senegenin Chemical compound C1[C@H](O)[C@H](O)[C@@](C)(C(O)=O)[C@@H]2CC[C@@]3(C)C(CC[C@]4(CCC(C[C@H]44)(C)C)C(O)=O)=C4[C@@H](CCl)C[C@@H]3[C@]21C CWHJIJJSDGEHNS-MYLFLSLOSA-N 0.000 description 1
- GDXWHFPKFUYWBE-UHFFFAOYSA-N [F].Cl Chemical compound [F].Cl GDXWHFPKFUYWBE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 102000004441 bcr-abl Fusion Proteins Human genes 0.000 description 1
- 108010056708 bcr-abl Fusion Proteins Proteins 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 231100000005 chromosome aberration Toxicity 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000009149 molecular binding Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000009871 tenuigenin Substances 0.000 description 1
- 238000003805 vibration mixing Methods 0.000 description 1
Images
Landscapes
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110189985.3A CN102353793B (zh) | 2011-07-07 | 2011-07-07 | 白血病细胞内融合蛋白的二元流式液相阵列检测方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110189985.3A CN102353793B (zh) | 2011-07-07 | 2011-07-07 | 白血病细胞内融合蛋白的二元流式液相阵列检测方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102353793A true CN102353793A (zh) | 2012-02-15 |
CN102353793B CN102353793B (zh) | 2014-01-29 |
Family
ID=45577394
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110189985.3A Active CN102353793B (zh) | 2011-07-07 | 2011-07-07 | 白血病细胞内融合蛋白的二元流式液相阵列检测方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102353793B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104471393A (zh) * | 2012-06-14 | 2015-03-25 | 鹿特丹伊拉斯姆斯大学医疗中心 | 用于检测微小残留病的方法、试剂以及试剂盒 |
CN107340225A (zh) * | 2017-07-13 | 2017-11-10 | 徐州医科大学 | 一种基于流式细胞术检测血小板受体GPIba胞外段酶切的方法 |
CN109813895A (zh) * | 2017-11-20 | 2019-05-28 | 中国农业大学 | 免疫壳聚糖磁性微球及其制备方法和在样品前处理中的应用 |
CN111077127A (zh) * | 2018-10-19 | 2020-04-28 | 东南大学 | 一种Bcr-Abl融合蛋白检测方法 |
CN111308075A (zh) * | 2020-03-18 | 2020-06-19 | 杭州广科安德生物科技有限公司 | 多肿瘤联合检测试剂盒及其使用方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1362623A (zh) * | 2002-01-21 | 2002-08-07 | 陕西超英生物医学研究开发有限公司 | 一种多元免疫微球、该多元免疫微球的制备技术以及对该多元免疫微球进行检测的方法 |
CN1820201A (zh) * | 2003-05-26 | 2006-08-16 | 佰赛泰克斯公司 | 使用微球体检测和多重定量样品中分析物的方法 |
CN101246173A (zh) * | 2007-10-22 | 2008-08-20 | 侯明 | 检测血小板特异性抗体的流式微球方法 |
WO2009134944A2 (en) * | 2008-04-29 | 2009-11-05 | Nodality, Inc. | Methods of determining the health status of an individual |
WO2010045651A1 (en) * | 2008-10-17 | 2010-04-22 | Nodality, Inc. | Methods for analyzing drug response |
CN101846676A (zh) * | 2010-05-10 | 2010-09-29 | 山东轻工业学院 | 一种氨基化微球的荧光编码方法 |
US20110104717A1 (en) * | 2008-07-10 | 2011-05-05 | Nodality, Inc. | Methods for diagnosis, prognosis and methods of treatment |
-
2011
- 2011-07-07 CN CN201110189985.3A patent/CN102353793B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1362623A (zh) * | 2002-01-21 | 2002-08-07 | 陕西超英生物医学研究开发有限公司 | 一种多元免疫微球、该多元免疫微球的制备技术以及对该多元免疫微球进行检测的方法 |
CN1820201A (zh) * | 2003-05-26 | 2006-08-16 | 佰赛泰克斯公司 | 使用微球体检测和多重定量样品中分析物的方法 |
CN101246173A (zh) * | 2007-10-22 | 2008-08-20 | 侯明 | 检测血小板特异性抗体的流式微球方法 |
WO2009134944A2 (en) * | 2008-04-29 | 2009-11-05 | Nodality, Inc. | Methods of determining the health status of an individual |
US20110104717A1 (en) * | 2008-07-10 | 2011-05-05 | Nodality, Inc. | Methods for diagnosis, prognosis and methods of treatment |
WO2010045651A1 (en) * | 2008-10-17 | 2010-04-22 | Nodality, Inc. | Methods for analyzing drug response |
CN101846676A (zh) * | 2010-05-10 | 2010-09-29 | 山东轻工业学院 | 一种氨基化微球的荧光编码方法 |
Non-Patent Citations (3)
Title |
---|
OWEN C. BLAIR等: "Differentiation of HL-60 promyelocytic leukemia cells: Simultaneous determination of phagocytic activity and cell cycle distribution by flow cytometry", 《CYTOMETRY》 * |
ROBERT F. VOGT JR.等: "Model system evaluating fluorescein-labeled microbeads as internal standards to calibrate fluorescence intensity on flow cytometers", 《CYTOMETRY》 * |
万岁桂等: "86例儿童急性淋巴细胞白血病三色流式细胞术免疫分型研究", 《中华血液学杂志》 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104471393A (zh) * | 2012-06-14 | 2015-03-25 | 鹿特丹伊拉斯姆斯大学医疗中心 | 用于检测微小残留病的方法、试剂以及试剂盒 |
CN104471393B (zh) * | 2012-06-14 | 2017-07-07 | 鹿特丹伊拉斯姆斯大学医疗中心 | 用于检测微小残留病的方法、试剂以及试剂盒 |
CN107340225A (zh) * | 2017-07-13 | 2017-11-10 | 徐州医科大学 | 一种基于流式细胞术检测血小板受体GPIba胞外段酶切的方法 |
CN107340225B (zh) * | 2017-07-13 | 2019-07-05 | 徐州医科大学 | 一种基于流式细胞术检测血小板受体GPIba胞外段酶切的方法 |
CN109813895A (zh) * | 2017-11-20 | 2019-05-28 | 中国农业大学 | 免疫壳聚糖磁性微球及其制备方法和在样品前处理中的应用 |
CN111077127A (zh) * | 2018-10-19 | 2020-04-28 | 东南大学 | 一种Bcr-Abl融合蛋白检测方法 |
CN111308075A (zh) * | 2020-03-18 | 2020-06-19 | 杭州广科安德生物科技有限公司 | 多肿瘤联合检测试剂盒及其使用方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102353793B (zh) | 2014-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103604931B (zh) | 一种人s100蛋白检测试剂及制备方法 | |
CN101036055B (zh) | 循环癌细胞上Her-2/neu蛋白的增加水平的检测以及治疗 | |
CN102353793B (zh) | 白血病细胞内融合蛋白的二元流式液相阵列检测方法 | |
CN107356744B (zh) | 一种循环肿瘤细胞分选和/或富集的方法及其试剂盒 | |
CN104034892A (zh) | 一种肿瘤标志物afp磁微粒化学发光免疫分析试剂盒及其检测方法 | |
CN102007413A (zh) | 抗环瓜氨酸肽抗体的检测方法 | |
CN113046422A (zh) | 基于免疫磁珠和滚环扩增的外泌体膜蛋白的流式检测方法及应用 | |
Yang et al. | Bead‐Based Extracellular Vesicle Analysis Using Flow Cytometry | |
CN103454431A (zh) | 检测β2微球蛋白的免疫比浊试剂盒及其制备方法 | |
CN108318690A (zh) | 一种免疫荧光层析试纸及其制备方法和应用 | |
CN104769429A (zh) | 体外诊断装置及其使用 | |
EP3243076A1 (en) | Methods for detecting a marker for active tuberculosis | |
US20200166528A1 (en) | Methods for Improving Assays of Biological Samples | |
CN102520176B (zh) | 一种定量检测白介素8的试剂盒 | |
CN109212189A (zh) | 一种定量检测血清、血浆中her-2蛋白含量的试剂盒 | |
WO2024001798A1 (zh) | 一种基于核酸适体的细胞外囊泡荧光极化检测方法及应用 | |
JP5348357B1 (ja) | 血中の目的細胞の定量方法および該細胞を定量するシステムの評価方法 | |
JPWO2018043584A1 (ja) | 異なる方式で抗原を固定化した抗原担持不溶性担体粒子を用いる抗体測定法、抗体測定用試薬 | |
Lee et al. | Immunostaining extracellular vesicles based on an aqueous two-phase system: For analysis of tetraspanins | |
CN111999225A (zh) | 一种微纳颗粒浓度的检测方法 | |
CN104741156B (zh) | 血小板筛选芯片及其制作方法和应用 | |
CN103376313A (zh) | 一种基于血清外来体检测急性冠脉综合征的液相芯片试剂盒及其制备方法 | |
CN103675277B (zh) | 流式细胞术鉴别诊断横纹肌肉瘤与神经母细胞瘤骨髓转移及白血病的荧光探针及试剂盒 | |
US20170089910A1 (en) | Methods and compositions for assaying blood levels of legumain | |
US20170227532A1 (en) | Method for producing a capture phase for the detection of a biological target, and associated detection methods and kits |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 250014 No. 58 Jiefang East Road, Lixia District, Shandong, Ji'nan Patentee after: Qilu University of Technology Address before: 250014 No. 58 Jiefang East Road, Lixia District, Shandong, Ji'nan Patentee before: Shandong Institute of Light Industry |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20221223 Address after: Room 3115, No. 135, Ward Avenue, Ping'an Street, Changqing District, Jinan, Shandong 250300 Patentee after: Shandong Jiqing Technology Service Co.,Ltd. Address before: 250014 No. 58 Jiefang East Road, Lixia District, Shandong, Ji'nan Patentee before: Qilu University of Technology |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230803 Address after: No. 632, Dujiamiao Village, Dougou Sub district Office, Shizhong District, Jinan City, Shandong Province, 250116 Patentee after: Shandong Quanli Biotechnology Co.,Ltd. Address before: Room 3115, No. 135, Ward Avenue, Ping'an Street, Changqing District, Jinan, Shandong 250300 Patentee before: Shandong Jiqing Technology Service Co.,Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Detection of fusion proteins in leukemia cells using binary flow cytometry liquid phase array Effective date of registration: 20231012 Granted publication date: 20140129 Pledgee: Qilu Bank Co Ltd Jinan Changqing University Road Branch Pledgor: Shandong Quanli Biotechnology Co.,Ltd. Registration number: Y2023980060984 |